Formulation and in vivo evaluation of omeprazole buccal adhesive tablet

Journal of Controlled Release

Volumn 68, Issue 3, 2000, Pages 405-412

  Choi, Han Gon ^a,b   Jung, Jac Hee ^c   Yong, Chul Soon ^b   Rhee, Chong Dal ^b   Lee, Mi Kyung ^a   Han, Jeong Hee ^a   Park, Kyung Mi ^a   Kim, Chong Kook ^a  

^a Seoul National University   (South Korea)

^b Yeungnam University   (South Korea)

^c DongWha Pharm Ind Co   (South Korea)

Author keywords

Buccal adhesive tablet; Croscarmellose sodium; Dissolution; Omeprazole; Pharmacokinetics

Indexed keywords

ALGINIC ACID; CROSCARMELLOSE SODIUM; HYDROXYPROPYLCELLULOSE; MAGNESIUM OXIDE; OMEPRAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG MIXTURE; DRUG RELEASE; DRUG SALIVA LEVEL; DRUG SOLUBILITY; DRUG STABILITY; FIRST PASS EFFECT; HAMSTER; HUMAN; MALE; NONHUMAN; PRIORITY JOURNAL; TABLET; TABLET MATRIX;

ADHESIVENESS; ADMINISTRATION, ORAL; ALGINATES; ANIMALS; ANTI-ULCER AGENTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHYSICAL; CRICETINAE; EVALUATION STUDIES; HUMANS; LACTOSE; MAGNESIUM OXIDE; MALE; MESOCRICETUS; METHYLCELLULOSE; MOUTH MUCOSA; OMEPRAZOLE; OXAZINES; TABLETS;

EID: 0034601666     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(00)00275-3     Document Type: Article

References (23)

1. Clissold S.P., Campoli-Richards D.M. Omeprazole: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic disease and Zollinger-Ellison syndrome. Drug. 32:1986;15-47.
2. Lee E.J., Han K.D., Shin H.J., Kim J.W., Kim C.K. Effect of L-arginine on the stability of omeprazole. J. Kor. Pharm. Sci. 27:1997;23-27.
3. Vezzadini P., Tommassetti P., Toni R., Bonora G., Labo G. Omeprazole in the medical treatment of Zollinger-Ellison syndrome. Curr. Ther. Res. 35:1984;772-776.
4. Andersson T., Bergstrand R., Cederberg C. Influence of acid secretory status on absorption of omeprazole from enteric coated granules. Br. J. Clin. Pharmacol. 31:1991;275-278.
5. Pilbrant A. Development of an oral formulation of omeprazole. Scan. J. Gastroenterol. 20:1985;113-119.
6. Kim C.K., Jeong E.J., Lee E.J., Shin H.J., Lee W.K. Bioequivalence of enteric coated omeprazole products. J. Kor. Pharm. Sci. 23:1993;41-49.
7. Thomsom A.B., Kirdeikis P., Lastiwka R., Rohss K., Sinclair P., Olofsson B. Pharmacokinetics and pharmacodynamics during treatment with the omeprazole 20 mg enteric coated tablet and 20 mg capsule in asymptomatic duodenal ulcer patients. Can. J. Gastroenterol. 11:1997;657-660.
8. Choi M.K., Chung S.J., Shim C.K. Rectal absorption of omeprazole from suppository in humans. J. Pharm, Sci. 85:1996;893-894.
9. H.G. Choi, C.K. Kim, Development of omeprazole buccal adhesive tablets with stability enhancement in human saliva, J. Control. Rel., 2000, accepted for publication.
10. Choi H.G., Oh Y.K., Kim C.K. In situ gelling and mucoadhesive liquid suppository containing acetaminophen: enhanced bioavailability. Int. J. Pharm. 165:1998;23-32.
11. Saito S., Sadamoto K., Ishikawa Y., Machida Y., Nagai T. Preparation and evaluation of oral mucosal adhesive film. Yakuzaiguaku. 50:1990;347-353.
12. Nakayama A., Oda M., Miyazaki S., Takada M. Oral mucosal adhesive tablets of indomethacin using chitosan and sodium alginate. Yakuzaiguaku. 54:1994;185-190.
13. Peppas N.A. Analysis of Fickian and non-Fickian drug release polymers. Pharm. Acta Helv. 60:1985;110-111.
14. Harris D., Robinson J.R. Drug delivery via the mucous membranes of the oral cavity. J. Pharm. Sci. 81:1992;1-10.
15. Kim C.K., Lee S.W., Choi H.G., Lee M.K., Gao Z.G., Kim I.S. Trials of in situ gelling and mucoadhesive acetaminophen liquid suppository in human subjects. Int. J. Pharm. 174:1998;201-207.
16. Lee Y., Chein Y.W. Oral mucosa controlled delivery of LHPH by bilayer mucoadhesive polymer systems. J. Control. Rel. 37:1995;251-261.
17. Lieberman H.A., Lachman L. Pharmaceutical Dosage Form: Tablets. Vol. 2:1988;116-161 Marcell Dekker, New York, Basel.
18. Yun M.O., Choi H.G., Jung J.H., Kim C.K. Development of thermoreversible insulin liquid suppository with bioavailability enhancement. Int. J. Pharm. 189:1999;137-145.
19. Choi H.G., Kim M.H., Lee M.K., Kim C.K. Effect of additives on the physicochemical properties of liquid suppository. Int. J. Pharm. 190:1999;13-19.
20. Choi H.G., Jung J.H., Ryu J.M., Yoon S.J., Oh Y.K., Kim C.K. Development of in situ gelling and mucoadhesive acetaminophen liquid suppository. Int. J. Pharm. 165:1998;33-44.
21. Tanaka M., Yanagibashi N., Fukuda H., Nagai T. Absorption of salicylic acid through the oral mucous membrane of hamster cheek pouch. Chem. Pharm. Bull. 28:1980;1056-1061.
22. Gerloff J., Mignot A., Barth H., Heintze K. Pharmacokinetics and absolute bioavailability of lansoprazole. Eur. J. Clin. Pharmacol. 50:1996;293-297.
23. Watanabe K., Furuno K., Eto K., Oishi R., Gomita Y. First-pass metabolism of omeprazole in rats. J. Pharm. Sci. 83:1994;1131-1134.